Dr Susana Banerjee MBBS MA PhD FRCP is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit. She is also Reader in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.
Dr Banerjee graduated with a 1st class from St John’s College, University of Cambridge, and completed her medical training at Royal Free Medical School where she was a University of London Gold Medal finalist. Dr Banerjee gained a PhD from The Institute of Cancer Research, University of London and was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Other prizes include the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize and the Pfizer British Oncology Association Young Investigator Award (highly commended).
Dr Banerjee has served in international specialist groups including the European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, ESGO (European Society of Gynaecological Oncology) Congress Faculty and International Gynecologic Cancer Society Scientific Program Committee. Dr Susana Banerjee was elected to be part of the European Society of Medical Oncology (ESMO) Executive Board as Director of Membership (2020-2022) and chairs the ESMO Resilience Task Force. She was Track Chair for Gynaecological Cancers for the ESMO Congress 2018, Scientific Co-Chair for ESMO Asia 2018 and Co-Chair of the ESMO Gynaecological Cancers Congress 2021 and 2022.
Dr Banerjee is an author of over 170 peer-reviewed publications including in the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research interests include individualisation of patient treatment, targeted therapies (including PARP inhibitors) and rare gynaecological cancers. Dr Banerjee has Global and UK Chief Investigator roles of multiple national and international clinical trials.